Compare RVT & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVT | SYRE |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | N/A | 2015 |
| Metric | RVT | SYRE |
|---|---|---|
| Price | $16.41 | $47.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $60.13 |
| AVG Volume (30 Days) | 224.3K | ★ 648.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.12 | $10.91 |
| 52 Week High | $18.73 | $45.79 |
| Indicator | RVT | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 69.94 |
| Support Level | $15.77 | $15.01 |
| Resistance Level | $16.50 | N/A |
| Average True Range (ATR) | 0.45 | 2.35 |
| MACD | -0.05 | 0.23 |
| Stochastic Oscillator | 25.00 | 86.51 |
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.